# A Randomized Trial of Novel Drug X in Patients with Hypertension

**Protocol Number:** RCT-DEMO-2024-001
**Principal Investigator:** Dr. Sarah Wilson, MD, PhD
**Study Phase:** Phase III
**Version:** 1.0
**Date:** February 04, 2026

## Protocol Synopsis

**Background:** This randomized controlled trial is designed to evaluate the efficacy and safety of the investigational treatment.

**Primary Objective:** To evaluate the efficacy of Drug X in reducing systolic blood pressure compared to placebo

**Secondary Objectives:** To assess safety, tolerability, and quality of life improvements

**Study Design:** Randomized, double-blind, placebo-controlled, parallel-group study

**Study Population:** Adults aged 18-75 with essential hypertension

**Sample Size:** 400 participants

## Study Objectives

### Primary Objective
To evaluate the efficacy of Drug X in reducing systolic blood pressure compared to placebo

### Secondary Objectives
To assess safety, tolerability, and quality of life improvements

## Study Design

**Design Type:** Parallel Group
**Randomization:** Central randomization with stratification
**Blinding:** Double-blind (participant and investigator)
**Treatment Duration:** 12 weeks

### Treatment Groups
- **Group A:** Investigational Drug
- **Group B:** Placebo

## Statistical Considerations

**Primary Endpoint:** Change from baseline in primary efficacy measure

**Sample Size Calculation:**
- Target Sample Size: 400 participants
- Power: 90%
- Alpha Level: 0.05
- Expected Effect Size: 0.5

**Statistical Analysis:** Mixed model repeated measures (MMRM) analysis

## Study Procedures

### Screening Period
Participants will undergo comprehensive screening to determine eligibility.

### Treatment Period  
Eligible participants will be randomized to receive either investigational treatment or placebo.

### Follow-up Period
Safety follow-up will continue for 30 days after last dose.

---

*This protocol was generated using the Enhanced Protocol Generation System with PHI compliance and regulatory framework support.*

**Generated:** 2026-02-04 04:26:54
**Template:** RCT Basic v1.0
**Compliance:** HIPAA, ICH-GCP
